Vyndaqel patent expir?

When can we expect the Vyndaqel patents to expire?
The patent life for most pharmaceuticals is 20 years from the filing date. Vyndaqel (vyndafyllin) was approved by the FDA in 2020, but the patents that cover it were filed earlier, most likely in the early‑to‑mid‑2010s. The exact expiration dates depend on the specific claims and filing dates, so the 20‑year rule alone does not give a single cutoff year.

How to find the precise expiration dates
Public patent databases list filing dates, granted dates, and calculated expiration dates.
- The U.S. Patent and Trademark Office (USPTO) provides a free search tool at patents.google.com where you can look up U.S. patents assigned to Vanda Pharmaceuticals or Novartis, the current owners.
- The European Patent Office (EPO) database, Espacenet, shows European patent filings and their status.
- The FDA’s Orange Book also lists product exclusivity periods that can indicate when a drug’s patent‑related exclusivity will end.

Who holds the Vyndaqel patents today?
Vyndaqel was originally developed by Vanda Pharmaceuticals, which was acquired by Novartis in 2021. The patents are now held by Novartis, which can file for additional patents or extensions such as terminal and supplementary protection certificates where applicable.

What might happen after the patents expire
When the primary patents lapse, other manufacturers can file for biosimilar versions, provided they meet regulatory requirements. In the U.S., the Biologics Price Competition and Innovation Act (BPCI‑A) sets the pathway for biosimilar approval, and once the patent term ends, the product can become eligible for competition.

Can the exclusivity period be extended
In some jurisdictions, exclusive marketing rights can be prolonged through mechanisms such as data exclusivity or supplementary protection certificates, which add additional years beyond the original patent life. However, these extensions are governed by national laws and are separate from the 20‑year patent term.

Where to see if any new patents were filed after approval
Search the USPTO and EPO databases for recent filings by Novartis that cite the original Vyndaqel patents. New patents can cover improved formulations or new therapeutic uses, potentially extending market exclusivity.

What if you’re a patient or clinician unsure about patent status
The most reliable source for the current exclusivity status is the FDA’s Orange Book or the European Medicines Agency (EMA) database. These resources list the dates of patent expiration and any applicable data exclusivity periods that affect market entry for generics or biosimilars.

Sources
1. U.S. Patent and Trademark Office, USPTO Patents Search: https://patents.google.com
2. European Patent Office, Espacenet: https://worldwide.espacenet.com
3. U.S. Food & Drug Administration, Orange Book: https://www.fda.gov/drugs/drug-safety-and-availability/green-book

These resources will give the most up‑to‑date information on Vyndaqel’s patent expiration and any related exclusivity periods.